Comparative Pharmacology
Head-to-head clinical analysis: FLAREX versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAREX versus OPHTHOCORT.
FLAREX vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that inhibits phospholipase A2 activity, reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes, thereby suppressing ocular inflammation.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
1-2 drops in the conjunctival sac every hour during the day and every 2 hours at night initially; after response, reduce to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours (mean 1.3 hours) in adults. Due to rapid clearance, accumulation is minimal with topical ophthalmic dosing, but prolonged use may lead to systemic absorption and slightly extended half-life.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism, with inactive metabolites excreted renally (approximately 60-80%) and fecally (20-40%). Less than 5% of unchanged drug appears in urine.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination